GRI Bio Statistics
Total Valuation
GRI Bio has a market cap or net worth of $1.70 million. The enterprise value is -$93,148.
| Market Cap | 1.70M |
| Enterprise Value | -93,148 |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GRI Bio has 3.20 million shares outstanding. The number of shares has increased by 257.82% in one year.
| Shares Outstanding | 3.20M |
| Shares Change (YoY) | +257.82% |
| Shares Change (QoQ) | +103.15% |
| Owned by Insiders (%) | 17.75% |
| Owned by Institutions (%) | 4.60% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.57 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.09 |
| Quick Ratio | n/a |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.26 |
Financial Efficiency
Return on equity (ROE) is -795.50% and return on invested capital (ROIC) is -4,171.06%.
| Return on Equity (ROE) | -795.50% |
| Return on Assets (ROA) | -345.40% |
| Return on Capital (ROIC) | -4,171.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.26M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.44% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -99.44% |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | 8.65 |
| Relative Strength Index (RSI) | 29.37 |
| Average Volume (30 Days) | 752,044 |
Short Selling Information
The latest short interest is 54,242, so 1.70% of the outstanding shares have been sold short.
| Short Interest | 54,242 |
| Short Previous Month | 115,733 |
| Short % of Shares Out | 1.70% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.39M |
| Pretax Income | -13.04M |
| Net Income | -13.04M |
| EBITDA | -10.95M |
| EBIT | -10.96M |
| Earnings Per Share (EPS) | -$28.25 |
Balance Sheet
The company has $1.81 million in cash and $14,000 in debt, giving a net cash position of $1.79 million or $0.56 per share.
| Cash & Cash Equivalents | 1.81M |
| Total Debt | 14,000 |
| Net Cash | 1.79M |
| Net Cash Per Share | $0.56 |
| Equity / Book Value | 259,000 |
| Book Value Per Share | 0.08 |
| Working Capital | 237,000 |
Cash Flow
In the last 12 months, operating cash flow was -$8.99 million and capital expenditures -$8,000, giving a free cash flow of -$9.00 million.
| Operating Cash Flow | -8.99M |
| Capital Expenditures | -8,000 |
| Free Cash Flow | -9.00M |
| FCF Per Share | -$19.50 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GRI Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -257.82% |
| Shareholder Yield | -257.82% |
| Earnings Yield | -766.50% |
| FCF Yield | -529.03% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 30, 2024. It was a reverse split with a ratio of 1:7.
| Last Split Date | Jan 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |